**Queensland**


**Subordinate Legislation 2001 No. 205**

***Health Act 1937***

# HEALTH (DRUGS AND POISONS) AMENDMENT REGULATION (No. 1) 2001

## TABLE OF PROVISIONS

## 1 Short title

This regulation may be cited as the *Health (Drugs and Poisons) Amendment Regulation (No. 1) 2001*.

## 2 Commencement

The following provisions of this regulation commence on the day fixed for the commencement of part 6 of the *Health Legislation Amendment Act 2001*—

(a) sections 39 and 40;

(b) section 44(6) and (8).

## 3 Regulation amended

This regulation amends the *Health (Drugs and Poisons) Regulation 1996.*

## 4 Replacement of s 5 (Meaning of "S2" to "S9")

Section 5—

*omit, insert—*

**'5 Meaning of "S2" to "S9"**

'**(1)** The expression **"S2"**, **"S3"**, **"S4"**, **"S5"**, **"S6"**, **"S7"**, **"S8"** or **"S9"**, if followed by a controlled drug, restricted drug or a poison, means the drug or poison in the schedule to the standard with the number given in the expression.

'**(2)** The expression **"S2"**, if followed by 'poison' or 'substance' without naming a poison or substance, means any poison in appendix 6A, items 1 to 10.

'**(3)** The expression **"S3"**, **"S4"**, **"S5"**, **"S6"**, **"S7"** or **"S8"**, if followed by 'poison' or 'substance' without naming a poison or substance, means any poison in the schedule to the standard with the number given in the expression.

'**(4)** The expression **"S9"**, if followed by 'poison' or 'substance' without naming a poison or substance, means any poison in appendix 6A, item 12.

*Examples—*

1. If a provision mentions 'S2 fluorides', it means fluorides in schedule 2 to the standard, i.e., fluorides in preparations for topical human therapeutic use.
2. If a provision mentions 'S3 fluorides', it means fluorides in schedule 3 to the standard, i.e., fluorides in dentifrices containing more than 1 000 mg/kg of fluoride ion. Fluorides may also be included in other schedules, for example as S5 or S6 poisons.
3. If a provision mentions 'S7 poison', it means any poison in schedule 7 to the standard.'.

## 5 Amendment of s 23 (Grounds for suspension or cancellation of endorsement)

Section 23—

*insert—*

'(e) the holder of the endorsement has contravened a provision of this regulation.'.

## 6 Insertion of new s 25A

After section 25—

*insert—*

### '25A Urgent cancellation of certain approvals

'**(1)** This section applies to each of the following approvals (a **"specified approval"**)—

(a) an approval mentioned in section 78(1)(a) for the treatment of a person by a doctor;[1]

(b) an approval under section 122,[2] other than an approval for the treatment of a class of drug dependent persons;

(c) an approval under section 213,[3] other than an approval for the treatment of a class of drug dependent persons.

---

1 Section 78 (Specified condition drugs—amphetamine, dexamphetamine, methylamphetamine, methylphenidate, phenmetrazine)

2 Section 122 (Approval needed for treating drug dependent person with controlled drugs)

3 Section 213 (Approval needed for treatment by doctor of drug dependent person with restricted drugs of dependency)

'**(2)** The chief executive may cancel a specified approval if the chief executive is reasonably satisfied—

(a) the holder of the specified approval (the **"former approval holder"**) has ceased to treat the person to whom the approval relates; and

(b) it is reasonably necessary, for the welfare of the person, for the chief executive to urgently give a specified approval to a doctor other than the former approval holder.

'**(3)** The chief executive must immediately give written notice of the decision to the former approval holder.

'**(4)** The notice must state—

(a) the reasons for the decision, including the reasons for cancelling the approval under this section; and

(b) that the former approval holder may appeal against the decision to a Magistrates Court within 28 days after receiving notice of the decision.

'**(5)** The decision takes effect on the later of—

(a) the day the notice is given to the former approval holder; or

(b) the day of effect stated in the notice.

'**(6)** For subsection (2)(a), the chief executive may be reasonably satisfied a former approval holder has ceased to treat a person regardless of—

(a) the reason the treatment ceased; or

(b) when the former approval holder last treated the person.'.

## 7 Amendment of s 32 (Surrender of endorsement)

Section 32—

*insert—*

'**(4)** Subsection (2) does not apply to an endorsement holder if the endorsement is an authority.'.

**8 Amendment of s 59A (Indigenous health workers)**

Section 59A, after 'area'—

*insert—*

'in a specified health service district'.

**9 Amendment of s 64 (Pharmacists)**

Section 64(1)(f), 'methadone syrup'—

*omit, insert—*

'a controlled drug'.

**10 Amendment of s 67 (Registered nurses)**

**(1)** Section 67(2), from 'an isolated', first mention, to 'registered'—

*omit, insert—*

'a rural hospital or an isolated practice area, a rural and isolated practice endorsed'.

**(2)** Section 67(2)(b), after 'drug'—

*insert—*

'in the rural hospital or'.

**11 Amendment of s 68 (Registered nurses at rural hospitals)**

Section 68, heading, '**Registered**'—

*omit, insert—*

'**Certain registered**'.

**12 Amendment of s 84 (Dealing with prescriptions and certain written instructions)**

**(1)** Section 84(1), ', for methadone syrup, when supplying'—

*omit, insert—*

'supplying a controlled drug'.

**(2)** Section 84(7), definition "relevant information"—

*omit, insert—*

' **"relevant information"**, for a prescription, means—

(a) the information appearing on the front of the prescription; and

(b) the information the dispenser is required to write on the prescription when dispensing the controlled drug.'.

## 13 Amendment of s 85 (Labelling dispensed and supplied medicines)

**(1)** Section 85(1)—

*omit, insert—*

'**(1)** A person who sells a controlled drug as a dispensed medicine or supplies a controlled drug on a written instruction (a **"supplied medicine"**), must securely attach to the dispensed or supplied medicine's container a label as required by this section with the following warnings printed on it—

(a) 'Keep out of reach of children';

(b) if the prescriber is a veterinary surgeon—'For animal treatment only'.

Maximum penalty—40 penalty units.'.

**(2)** Section 85(3)(a), from 'for' to 'syrup'—

*omit, insert—*

'(a) for a dispensed or supplied medicine for human use'.

**(3)** Sections 85(3)(c) and (e), 'medicine or methadone syrup'—

*omit, insert—*

'or supplied medicine'.

**(4)** Sections 85(3)(f) and (g), 'medicine or methadone syrup'—

*omit, insert—*

'dispensed or supplied medicine'.

**(5)** Section 85(5)—

*omit, insert—*

'**(5)** Despite subsection (1), a person is not required to attach a label to a supplied medicine's container if—

(a) the person supplies the medicine under section 64(1)(f);[4] and

(b) the medicine is ingested by the person to whom it is supplied in the presence of the person who supplies it.'.

## 14 Amendment of s 94 (Unlawful possession of controlled drugs)

Section 94(2), definition "controlled drug", '*Drugs Misuse Act 1986*'—

*omit, insert—*

'*Drugs Misuse Regulation 1987*'.

## 15 Amendment of s 112 (Records—ambulance officers and isolated practice endorsed registered nurses)

Section 112, 'isolated practice endorsed registered'—

*omit, insert—*

'rural and isolated practice endorsed'.

## 16 Amendment of s 113 (Record keeping for nursing practice in isolated practice area)

Section 113(1), 'isolated practice endorsed registered'—

*omit, insert—*

'rural and isolated practice endorsed'.

## 17 Amendment of s 119 (Storage of controlled drugs generally)

**(1)** Section 119(1)(b)—

*omit, insert—*

---

4 Under section 64(1)(f), a pharmacist is authorised to supply a controlled drug, under a drug therapy protocol, on the oral or written instruction of a doctor who holds an approval under section 122(5) or (6).

'(b) in another place (a **"secure place"**) an inspector who inspects the place is reasonably satisfied is at least as secure as a receptacle mentioned in paragraph (a).'.

**(2)** Section 119(2)(a), before 'place locked'—

*insert—*

'secure'.

**(3)** Section 119(4) and (5), 'isolated practice endorsed registered'—

*omit, insert—*

'rural and isolated practice endorsed'.

## 18 Amendment of s 149 (Storage etc. of samples)

Section 149(2)—

*omit, insert—*

'**(2)** If the representative supplies a restricted drug to a dentist, doctor or veterinary surgeon (a **"practitioner"**), the representative must—

(a) before supplying the drug—

(i) personally give the practitioner an invoice that complies with subsection (4) for the drug; and

(i) personally receive from the practitioner a copy of the invoice signed by the practitioner; and

(b) send a copy of the signed invoice to the representative's employer within 7 days after the day of supply.

Maximum penalty—40 penalty units.'.

## 19 Insertion of new s 163A

After section 163—

*insert—*

### '163A Hospital pharmaceutical assistants

'To the extent necessary to perform the person's pharmaceutical imprest duties in a hospital, a hospital pharmaceutical assistant acting under the supervision of a pharmacist in the hospital, is authorised to—

(a) possess a restricted drug (other than a restricted drug of dependency or a regulated restricted drug) at the hospital; or

(b) issue a restricted drug (other than a restricted drug of dependency or a regulated restricted drug) to an authorised person for treatment of the hospital's patients.'.

## 20 Amendment of s 164A (Indigenous health workers)

**(1)** Section 164A, after 'area'—

*insert—*

'in a specified health service district'.

## 21 Amendment of s 172 (Podiatrists)

Section 172(c), 'practices'—

*omit, insert—*

'practises'.

## 22 Amendment of s 175 (Registered nurses)

**(1)** Section 175(2), from 'an isolated', first mention, to 'registered'—

*omit, insert—*

'a rural hospital or an isolated practice area, a rural and isolated practice endorsed'.

**(2)** Section 175(2)(b), after 'drug'—

*insert—*

'in the rural hospital or'.

**(3)** Section 175(2)(b), 'practices'—

*omit, insert—*

'practises'.

**(4)** Section 175(3), from 'endorsed' to 'program is'—

*omit, insert—*

'whose annual licence certificate is endorsed under the *Nursing Act 1992* for practice in an immunisation program is'.

**(5)** Section 175(4), from 'endorsed' to 'program is'—

*omit, insert—*

'whose annual licence certificate is endorsed under the *Nursing Act 1992* for practice in a sexual health program is'.

**(6)** Section 175(5)—

*omit.*

## 23 Amendment of s 176 (Registered nurses at rural hospitals)

Section 176, heading, '**Registered**'—

*omit, insert—*

'**Certain registered**'.

## 24 Amendment of s 186 (Acitretin, etretinate, isotretinoin and tretinoin)

**(1)** Section 186(1), from ', isotretinoin' to 'human'—

*omit, insert—*

'or tretinoin for human therapeutic use or isotretinoin for human oral'.

**(2)** Section 186(1)(a), 'for human therapeutic use'—

*omit.*

**(3)** Section 186(3)—

*omit, insert—*

'**(3)** Despite subsection (1)—

(a) a person for whose therapeutic use acitretin, etretinate or tretinoin is dispensed, prescribed or sold under subsection (1) may obtain or use acitretin, etretinate or tretinoin; or

(b) a person for whose oral therapeutic use isotretinoin is dispensed, prescribed or sold under subsection (1) may obtain or use isotretinoin.'.

**25 Amendment of s 186A (Thalidomide)**

**(1)** Section 186A, heading—

*omit, insert—*

'**Bexarotene and thalidomide**'.

**(2)** Section 186A, before 'thalidomide for'—

*insert—*

'bexarotene or'.

**26 Amendment of s 187 (Clomiphene, cyclofenil, luteinising hormone and urofollitrophin)**

**(1)** Section 187(1), 'regulated restricted'—

*omit, insert—*

'section 187'.

**(2)** Section 187(1)—

*insert—*

'(c) is a registrar in obstetrics and gynaecology or internal medicine working directly under the supervision of a specialist in obstetrics and gynaecology or internal medicine.'.

**(3)** Section 187(2), from ' "regulated' to 'following'—

*omit, insert—*

' **"section 187 drug"** means any of the following regulated'.

**27 Amendment of s 189 (Exemptions for some acts involving certain regulated restricted drugs)**

**(1)** Section 189(1) 'regulated restricted'—

*omit, insert—*

'section 189'.

**(2)** Section 189(2), from ' "regulated' to 'following'—

*omit, insert—*

' **"section 189 drug"** means any of the following regulated'.

**28 Amendment of s 204 (Unlawful possession of restricted drugs)**

Section 204(2), definition "restricted drug", '*Drugs Misuse Act 1986*'—

*omit, insert—*

'*Drugs Misuse Regulation 1987*'.

**29 Amendment of s 207 (Records of restricted drugs supplied to be kept)**

Section 207(1A)(a), 'an isolated practice endorsed registered'—

*omit, insert—*

'a rural and isolated practice endorsed'.

**30 Amendment of s 211 (Storage of restricted drugs generally)**

Section 211(2) and (3), 'isolated practice endorsed registered'—

*omit, insert—*

'rural and isolated practice endorsed'.

**31 Amendment of s 229 (Poison wholesaler licence)**

Section 229(1), 'Subject to section 235, a'—

*omit, insert—*

'A'.

**32 Amendment of s 252A (Indigenous health workers)**

**(1)** Section 252A, after 'area'—

*insert—*

'in a specified health service district'.

**(2)** Section 252A—

*renumber* as section 252B.

**33 Insertion of new s 252A**

After section 252—

*insert—*

**'252A Hospital pharmaceutical assistants**

'To the extent necessary to perform the person's pharmaceutical imprest duties in a hospital, a hospital pharmaceutical assistant acting under the supervision of a pharmacist in the hospital, is authorised to issue an S2 or S3 poison to an authorised person for treatment of the hospital's patients.'.

**34 Amendment of s 254 (Local governments)**

Section 254(b)—

*omit, insert—*

'(b) sell sodium fluoride in a form containing a concentration of not more than 2.2 mg of sodium fluoride in each dosage unit.'.

**35 Amendment of s 263 (Registered nurses)**

Section 263(2), from 'an isolated practice area'—

*omit, insert—*

'a rural hospital or an isolated practice area, a rural and isolated practice endorsed nurse is authorised to supply an S2 or S3 poison to or for a person requiring treatment at the rural hospital or in the isolated practice area.'.

**36 Amendment of s 263A (Registered nurses at rural hospitals)**

Section 263A, heading, '**Registered**'—

*omit, insert—*

'**Certain registered**'.

**37 Amendment of s 273A (Wholesale and retail sales by manufacturers and wholesalers)**

**(1)** Section 273A(2)(b)(iii), 'an isolated practice endorsed registered'—

*omit, insert—*

'a rural and isolated practice endorsed'.

**(2)** Section 273A(2)(b)—

*insert—*

'(v) the vice-chancellor of a university; or'.

**(3)** Section 273A(2)(c)(i), 'paragraph (a)'—

*omit, insert—*

'paragraph (b)'.

### 38 Amendment of s 286 (Prohibition on dispensing or supplying poisons to child under 16)

**(1)** Section 286(3), 'a registered' to 'area'—

*omit, insert—*

'a rural and isolated practice endorsed nurse'.

**(2)** Section 286(4)—

*omit.*

### 39 Omission of ch 5, pt 1 and ss 306 and 307

Chapter 5, part 1 and sections 306 and 307—

*omit.*

### 40 Amendment of ch 5, pts 2 and 3

Chapter 5, parts 2 and 3—

*renumber* as parts 1 and 2.

**41 Amendment of appendix 3 (Who must sign certain purchase orders for controlled or restricted drugs)**

Appendix 3, part 2—

*insert—*

| | |
|---|---|
| '**14.** university | the university's vice-chancellor or a person to whom the vice-chancellor has delegated authority under section 179A(2)'. |

**42 Insertion of new appendix 6A**

After appendix 6—

*insert—*

## 'APPENDIX 6A

## 'POISONS

appendix 9, definition "poison"

**1.** Atropine (other than atropine methonitrate)—

(a) in preparations containing 0.25% or less of atropine; or

(b) in tablets, each containing 0.6 mg of atropine sulfate, in a pack that contains 20 tablets and is labelled for treatment of organophosphorus poisoning.

**2.** Belladonna in preparations containing 0.25% or less of the alkaloids of belladonna.

**3.** Datura spp. in preparations containing 0.25% or less of the alkaloids of datura.

**4.** Duboisia leichhardtii in preparations containing 0.25% or less of the alkaloids of duboisia.

**5.** Duboisia myoporoides in preparations containing 0.25% or less of the alkaloids of duboisia.

**6.** Hyoscine (other than hyoscine butylbromide)—

(a) in preparations containing 0.25% or less of hyoscine; or

(b) in transdermal applicators containing 2 mg or less of hyoscine.

**7.** Hyoscyamine in preparations containing 0.25% or less of hyoscyamine.

**8.** Hyoscyamus in preparations containing 0.25% or less of hyocyamus.

**9.** Stramonium in preparations containing 0.25% or less of the alkaloids of stramonium, other than in preparations for smoking or burning.

**10.** A substance mentioned in schedule 2 to the standard, other than the following substances—

(a) atropine (other than atropine methonitrate)—

(i) for oral use in undivided preparations containing 0.025% or less of atropine when labelled with a dose of 0.025 mg or less of atropine and a recommended daily dose of 0.5 mg or less of atropine; or

(ii) for oral use in divided preparations containing 0.025 mg or less of atropine per dosage unit when labelled with a recommended daily dose of 0.5 mg or less of atropine; or

(iii) in preparations containing atropine sulfate when packed and labelled for the treatment of organophosphorus poisoning in tablets each containing 0.6 mg or less of atropine sulfate in packs of 20 tablets or in preparations for injection each

containing 0.6 mg per ml or less of atropine sulfate in packs of 5;

(b) atropa belladonna (belladonna)—

(i) for external use in preparations containing 0.025% or less of the alkaloids of belladonna; or

(ii) for oral use in undivided preparations containing 0.025% or less of the alkaloids of belladonna when labelled with a dose of 0.025 mg or less of the alkaloids of belladonna and a recommended daily dose of 0.5 mg or less of the alkaloids of belladonna; or

(iii) for oral use in divided preparations containing 0.025 mg or less of the alkaloids of belladonna per dosage unit when labelled with a recommended daily dose of 0.5 mg or less of the alkaloids of belladonna;

(c) datura spp. for oral use—

(i) in undivided preparations containing 0.025% or less of the alkaloids of datura when labelled with a dose of 0.3 mg or less of the alkaloids of datura and a recommended daily dose of 1 mg or less of the alkaloids of datura; or

(ii) in divided preparations containing 0.3 mg or less of the alkaloids of datura per dosage unit when labelled with a recommended daily dose of 1 mg or less of the alkaloids of datura;

(d) datura stramonium (stramonium) for oral use—

(i) in undivided preparations that are not for smoking or burning and contain 0.025% or less of the alkaloids of stramonium when labelled with a dose of 0.025 mg or less of the alkaloids of stramonium and a recommended daily dose of 0.5 mg or less of the alkaloids of stramonium; or

(ii) in divided preparations that are not for smoking or burning and contain 0.025 mg or less of the alkaloids of stramonium per dosage unit when labelled with a recommended daily dose of 0.5 mg or less of the alkaloids of stramonium;

(e) datura tatula (stramonium) for oral use—

(i) in undivided preparations that are not for smoking or burning and contain 0.025% or less of the alkaloids of

stramonium when labelled with a dose of 0.025 mg or less of the alkaloids of stramonium and a recommended daily dose of 0.5 mg or less of the alkaloids of stramonium; or

(ii) in divided preparations that are not for smoking or burning; and contain 0.025 mg or less of the alkaloids of stramonium per dosage unit when labelled with a recommended daily dose of 0.5 mg or less of the alkaloids of stramonium;

(f) duboisia leichardtii for oral use—

(i) in undivided preparations containing 0.025% or less of the alkaloids of duboisia calculated as hyoscyamine when labelled with a dose of 0.025 mg or less of the alkaloids of duboisia calculated as hyoscyamine and a recommended daily dose of 0.5 mg or less of the alkaloids of duboisia calculated as hyoscyamine; or

(ii) in divided preparations containing 0.025 mg or less of the alkaloids of duboisia calculated as hyoscyamine per dosage unit when labelled with a recommended daily dose of 0.5 mg or less of the alkaloids of duboisia calculated as hyoscyamine;

(g) duboisia myoporoides for oral use—

(i) in undivided preparations containing 0.025% or less of the alkaloids of duboisia calculated as hyoscyamine when labelled with a dose of 0.025 mg or less of the alkaloids of duboisia calculated as hyoscyamine and a recommended daily dose of 0.5 mg or less of the alkaloids of duboisia calculated as hyoscyamine; or

(ii) in divided preparations containing 0.025 mg or less of the alkaloids of duboisia calculated as hyoscyamine per dosage unit when labelled with a recommended daily dose of 0.5 mg or less of the alkaloids of duboisia calculated as hyoscyamine;

(h) hyoscine (other than hyoscine butylbromide)—

(i) for transdermal use in preparations containing 2 mg or less of hyoscine; or

(ii) for oral use in undivided preparations containing 0.025% or less of hyoscine when labelled with a dose of 0.3 mg or less

of hyoscine and a recommended daily dose of 1 mg or less of hyoscine; or

(iii) for oral use in divided preparations containing 0.3 mg or less of hyoscine per dosage unit when labelled with a recommended daily dose of 1 mg or less of hyoscine;

(i) hyoscyamine—

(i) for external use in preparations containing 0.025% or less of hyoscyamine; or

(ii) for oral use in undivided preparations containing 0.025% or less of hyoscyamine when labelled with a dose of 0.025 mg or less of hyoscyamine and a recommended daily dose of 0.5 milligrams or less of hyoscyamine; or

(iii) for oral use in divided preparations containing 0.025 mg or less of hyoscyamine per dosage unit when labelled with a recommended daily dose of 0.5 mg or less hyoscyamine;

(j) hyoscyamus niger for oral use—

(i) in undivided preparations containing 0.025% or less of the alkaloids of hyoscyamus when labelled with a dose of 0.025 mg or less of the alkaloids of hyoscyamus and a recommended daily dose of 0.5 mg or less of the alkaloids of hyoscyamus; or

(ii) in divided preparations containing 0.025 mg of the alkaloids of hyoscyamus or less per dosage unit when labelled with a recommended daily dose of 0.5 mg or less of the alkaloids of hyoscyamus.

**11.** An S3, S5, S6 or S7 substance.

**12.** A substance mentioned in schedule 9 to the standard other than—

(a) cannabis sativa when used for plant breeding or research purposes if—

(i) the leaves and flowering heads do not contain more than 1% of tetrahydrocannabinol; and

(ii) the seeds do not contain more than 0.35% of tetrahydrocannabinol; or

(b) cannabis sativa when used in field trials if the leaves, flowering heads and seeds do not contain more than 0.35% of tetrahydrocannabinol.

**13.** A substance mentioned in appendix C of the standard.'.

### 43 Insertion of new appendix 7A

After appendix 7—

*insert—*

## 'APPENDIX 7A

## 'RESTRICTED DRUGS

appendix 9, definition "restricted drug"

**1.** Alkaloids and alkaloidal glycosides of plants of the genus solanum for human therapeutic use.

**2.** An S4 substance other than the following—

- atropa belladonna (belladonna)
- datura stramonium
- hyoscyamus niger
- solasadine.

**3.** Belladonna, other than S2 belladonna.

**4.** Hyoscyamus, other than S2 hyoscyamus.

**5.** Stramonium, other than S2 stramonium or stramonium in preparations for smoking or burning.'.

## 44 Amendment of appendix 9 (Dictionary)

**(1)** Appendix 9, definitions, "isolated practice endorsed", "poison", "regulated drug" and "restricted drug"—

*omit.*

**(2)** Appendix 9—

*insert—*

' **"hospital"** means a public sector hospital or private hospital.

**"hospital pharmaceutical assistant"** means an adult person who—

(a) has a qualification or statement of attainment issued under the *Training and Employment Act 2000* by a registered training organisation, recognising the person has the skills and knowledge required to perform pharmaceutical imprest duties in a hospital; and

(b) performs pharmaceutical imprest duties in a hospital.

**"pharmaceutical imprest duties"** means duties related to keeping an inventory of drugs obtained for use at a hospital or issued for treatment of the hospital's patients.

**"poison"** means a poison in appendix 6A of this regulation.

**"registered training organisation"**, see *Training and Employment Act 2000*, section 14.

**"regulated controlled drug"** means a controlled drug mentioned in chapter 2, part 3.

**"regulated restricted drug"** means a restricted drug mentioned in chapter 3, part 3.

**"restricted drug"** means a drug in appendix 7A of this regulation.

**"rural and isolated practice endorsed nurse"** means a registered nurse whose annual licence certificate is endorsed under the *Nursing Act 1992* for practice as a rural and isolated practice nurse.

**"specified health service district"** means any of the following health service districts declared under the *Health Services Act 1991*[5]—

- Cairns
- Cape York
- Mount Isa
- Torres Strait and Northern Peninsula Area.

**"statement of attainment"**, for a hospital pharmaceutical assistant, see *Training and Employment Act 2000*, schedule 3.[6]'.

**(3)** Appendix 9, definition "ECP area", 'an ECP area'—

*omit, insert—*

'an ECP[7] area'.

**(4)** Appendix 9, definition "endorsement", paragraph (a), 'or'—

*omit.*

**(5)** Appendix 9, definition "indigenous health worker", paragraph (c)—

*omit.*

**(6)** Appendix 9, definition "inspector", 'section 27'—

*omit, insert—*

'section 137[8]'.

**(7)** Appendix 9, definition "licensee", paragraph (a)(ii), 'restricted'—

*omit, insert—*

'controlled'.

---

5 *Health Services Act 1991*, section 6 (Health service districts)

6 *Training and Employment Act 2000*, schedule 3 (Dictionary)—

**"statement of attainment"** means a certification recognising that a person has achieved 1 or more of the learning outcomes identified for a particular qualification or accredited course.

7 "ECP" is an acronym used by the Queensland Ambulance Service for "extended care program".

8 Section 137 (Appointment and qualifications) of the Act.

**(8)** Appendix 9, definition "State analyst", 'section 27'—

*omit, insert—*

'section 153Z(1)[9]'.

**(9)** Appendix 9, definition "treatment approval", paragraphs (a), (b) and (c)—

*renumber* as paragraphs (b), (c) and (d).

**(10)** Appendix 9, definition "treatment approval"—

*insert—*

'(a) an approval given to a doctor by the chief executive under section 78(1)(a);'.

**(11)** Appendix 9, definition "Veterans Entitlements Act", '*Veterans Entitlements Act 1990* (Cwlth)'—

*omit, insert—*

'*Veterans' Entitlements Act 1986* (Cwlth)'.

ENDNOTES

1. Made by the Governor in Council on 15 November 2001.
2. Notified in the gazette on 16 November 2001.
3. Laid before the Legislative Assembly on . . .
4. The administering agency is the Department of Health.



9 Section 153Z (Appointment and qualifications) of the Act.